Tag Archives: MA

Why Perfection is Overrated

By Roberta Matuson, Contributor

Eventually it was bound to happen. I experienced an evening at my favorite restaurant Barcelona, in Brookline, MA, which wasn’t perfect. I’ve been to this place a number of times and have always walked away completely impressed with the food and quite satisfied with the service. However, this was not the case on my last visit. …read more

Source: FULL ARTICLE at Forbes Latest

Watch These Most Overbought S&P 500 Stocks

By Tom Aspray, Contributor

It was another positive week for stocks as the Dow Transportation Average led the way, gaining 2.3%, followed by a 1.2% gain in the Dow Utilities. Small caps were also strong with the Russell 2000 over 1.3%. Oil and gas was the top industry group, up over 2%, while the technology sector was hit hard as Microsoft Corp. (MSFT) was down 11% last Friday after testing its daily starc+ band early in the week. Given the S&P 500’s rally from the late June lows, I was cautious in last week’s column Should You Be Buying Now even though I acknowledged that another 1-3% on the upside was still possible. There are still no signs of a top with first support at last Wednesday’s low. In determining whether a new position should be established or not, you have to consider whether you are buying near resistance or selling near support. By determining your stop level, you can determine the risk, which should determine whether the position is taken or not. Focusing on risk is the key because if you take too many high-risk positions, the odds of success are not in your favor. Click to Enlarge My weekly starc band scan of the stocks in the S&P 500 reveals that quite a few stocks closed last week above their weekly starc+ bands. As a reference, the Spyder Trust (SPY) closed last Friday just 1.5% below its weekly starc+ band. It is important to remember that just because a stock closes above its weekly starc+ band (overbought), it does not mean that the stock cannot still move even higher. But each consecutive week a stock closes either above its starc+ or below its starc- band (oversold), the odds increase that prices will at least consolidate, if not reverse. In the summer of 2011, the consecutive closes in gold above the monthly starc+ bands warned of a significant trend change. On the table, I have also included the % that they are above their 200-day moving average. The first eight stocks on the list are above their weekly starc+ bands. While that does not mean they can’t still go higher, they are a high-risk buy at current levels. At the top of the list is Xilinx Inc. (XLNX), which closed last week 1.6% above its starc+ band and is 12.5% above its 50-day MA. It is also important to determine whether the stock is above or below long-term resistance. Let’s look at the four most interesting stocks on the list. Click to Enlarge Chart Analysis: Xilinx Inc. (XLNX) is a $12.1 billion dollar semi-conductor company that reported earnings last week that their 1st quarter net income was up 21%. Since the June low of $37.63, it is up 21.9% and has already exceeded the quarterly R2 resistance. The first support is in the $42.60 area, 7.1% below Friday’s close, which is quite a bit of risk. There is more important support at $41.47, which was the May high. The weekly chart has multi-year …read more

Source: FULL ARTICLE at Forbes Latest

Erakat, a veteran voice of the Palestinians

Long-time Palestinian negotiator Saeb Erakat was announced on Friday as the man to open dialogue with his Israeli counterpart at meetings in Washington after three years of stalled peace negotiations.

Both Erakat and Israel’s Justice Minister Tzipi Livni will meet US Secretary of State John Kerry for initial talks, the top US diplomat said at the end of four days of intense diplomacy as he consulted Palestinian and Israeli leaders from his base in Amman.

The 55-year-old Erakat, an academic whose perfect command of English is often spiced with humour, was part of every team to negotiate with Israel since 1991, with the notable exception of those who secretly hammered out the 1993 Oslo Accords.

Erakat rose to prominence as a media personality at the 1991 international peace conference in Madrid at which he wore the black-and-white chequered Palestinian headscarf.

Born in Jerusalem, he has been a key figure in the Palestinian political landscape, an indispensable briefer for foreign envoys and a suave tactician who can register indignation when necessary.

A member of the Palestinian parliament since 1996, Erakat was close to Yasser Arafat, historic leader of the Palestinian national movement, even though he did not follow Arafat into exile in Jordan, Lebanon and Tunisia before his return to Gaza in 1994.

In 2009, Erakat was elected to the central committee of the Fatah wing of Mahmud Abbas’s Palestinian Authority and to the executive committee of the Palestine Liberation Organisation.

He was an architect of the negotiations on a final settlement of the Israeli-Palestinian conflict, from the failed Camp David summit in July 2000 to the talks launched in Washington in September 2010 which were interrupted after less than a month in a row over Israel’s continued settlement building.

Appointed in 2003 to head the PLO negotiating team, Erakat briefly resigned from the post in 2011 because of “responsibility for the theft of documents from his office,” papers which he said had been “adulterated”.

He was referring to more than 1,600 documents on the talks with Israel between 1999 and 2010, released in January 2011 by Qatar-based satellite channel Al-Jazeera and dubbed “The Palestine Papers”.

Palestinian officials worked to limit the damage caused by their publication, which showed Palestinian negotiators prepared to offer significant concessions without securing Israeli guarantees on key issues such as east Jerusalem and the fate of refugees.

Although the documents did not cause major turmoil in Palestinian public opinion, Erakat’s position was weakened at the time by announcements the alleged perpetrators of the leaks worked for the PLO negotiation team he headed.

He had said an investigation into the leaks pointed towards three nationals of US, British and French extraction being responsible.

A former journalist with the independent daily Al-Quds in east Jerusalem, Erakat holds a BA and an MA in Political Science from the University of San Francisco.

He also has a doctorate in Peace Studies from the University of Bradford in England, and he taught at An-Najah University in the West Bank town of Nablus from 1979 to 1991.

Erakat has written a dozen books and lives in the …read more

Source: FULL ARTICLE at Fox World News

Remarks by the President to First Responders and Volunteers in Boston, MA

By The White House

Cathedral High School
Boston, Massachusetts

12:35 P.M. EDT

THE PRESIDENT: Thank you. Thank you, everybody. Well, listen, we just had a wonderful interfaith service, and I want to thank Governor Patrick for helping to organize that. I want to thank both the Governor and your extraordinary Mayor, Tom Menino — (applause) — for the incredible leadership and cool under pressure, the organization, the mobilization and the courage that they have shown reflective of this great city and reflective of this great Commonwealth of Massachusetts.

Now, I’m not going to speak long. I’m just — he started calling me Reverend Obama, so I know — (laughter) — I know I was — I don't want to go on any longer than I need to. The main message, in addition to just giving — having a chance to shake some hands and give some hugs, is just to say how proud the whole country is of you — (applause) — how grateful we are — how grateful we are that in the face of chaos and tragedy, all of you displayed the very best of the American spirit.

You displayed grit. You displayed compassion. You displayed civic duty. You displayed courage. And when we see that kind of spirit, there’s something about that that's infectious. It makes us all want to be better people. You’ve inspired the entire country. You’ve inspired the world. And for that, you should be profoundly proud.

But as Deval and I were talking as we were driving in from the airport, the key is that we hang on to a little bit of that, because it’s right there under the surface every day. And it expresses itself, obviously, in the Marathon. It expresses itself in Patriot’s Day. It expresses itself in all the small interactions, the gestures of kindness and generosity and tolerance and compassion that make up the fabric of our lives. And we don't always pay attention to it, and we don't always celebrate, and it’s certainly not usually on a television screen, it’s not always reported on. But that's who we are.

And if there’s anything that was a theme in that interfaith service it’s that out of these ashes, out of the blood that's spilled and the injuries borne, out of that, we get a chance to see and highlight and appreciate that spirit. And we’ve got to sustain it, because in all of our lives at some point there are going to be some troubles, and there’s evil in the world, and there’s hardship. But if that spirit is evident and manifest, and that's what we’re teaching our kids and that's what we’re embodying in our own lives, then who can stop us? Who can touch us? (Applause.)

So thank you, everybody. I’m proud of you. I’m proud of Boston. And as I just said, I’m looking forward to the 118th

From: http://www.whitehouse.gov/the-press-office/2013/04/18/remarks-president-first-responders-and-volunteers-boston-ma

Remarks by the President at Interfaith Service in Boston, MA

By The White House

Cathedral of The Holy Cross
Boston, Massachusetts

12:04 P.M. EDT

THE PRESIDENT: Hello, Boston!

Scripture tells us to “run with endurance the race that is set before us.” Run with endurance the race that is set before us.

On Monday morning, the sun rose over Boston. The sunlight glistened off the Statehouse dome. In the Common and the Public Garden, spring was in bloom. On this Patriot’s Day, like so many before, fans jumped onto the T to see the Sox at Fenway. In Hopkinton, runners laced up their shoes and set out on a 26.2-mile test of dedication and grit and the human spirit. And across this city, hundreds of thousands of Bostonians lined the streets — to hand the runners cups of water and to cheer them on.

It was a beautiful day to be in Boston — a day that explains why a poet once wrote that this town is not just a capital, not just a place. Boston, he said, “is the perfect state of grace.” (Applause.)

And then, in an instant, the day’s beauty was shattered. A celebration became a tragedy. And so we come together to pray, and mourn, and measure our loss. But we also come together today to reclaim that state of grace — to reaffirm that the spirit of this city is undaunted, and the spirit of this country shall remain undimmed.

To Governor Patrick; Mayor Menino; Cardinal O’Malley and all the faith leaders who are here; Governors Romney, Swift, Weld and Dukakis; members of Congress; and most of all, the people of Boston and the families who’ve lost a piece of your heart. We thank you for your leadership. We thank you for your courage. We thank you for your grace.

I’m here today on behalf of the American people with a simple message: Every one of us has been touched by this attack on your beloved city. Every one of us stands with you.

Because, after all, it’s our beloved city, too. Boston may be your hometown, but we claim it, too. It’s one of America’s iconic cities. It’s one of the world’s great cities. And one of the reasons the world knows Boston so well is that Boston opens its heart to the world.

Over successive generations, you’ve welcomed again and again new arrivals to our shores — immigrants who constantly reinvigorated this city and this commonwealth and our nation. Every fall, you welcome students from all across America and all across the globe, and every spring you graduate them back into the world — a Boston diaspora that excels in every field of human endeavor. Year after year, you welcome the greatest talents in the arts and science, research — you welcome them to your concert halls and your hospitals and your laboratories to exchange ideas and insights that draw this world together.

And every third Monday in

From: http://www.whitehouse.gov/the-press-office/2013/04/18/remarks-president-interfaith-service-boston-ma

Press Gaggle by Principal Deputy Press Secretary Josh Earnest Aboard Air Force One en route Boston, MA

By The White House

Aboard Air Force One
En Route Boston, Massachusetts

9:35 A.M. EDT

MR. EARNEST: Good morning, everybody. Welcome aboard Air Force One as we make our way to Boston. I have a couple of updates that I'll walk through before we open it up to questions.

The first is you all have received an email overnight that the President signed a disaster declaration for the state of Massachusetts. This will make additional federal resources available to state and local officials who are responsible for responding to the bombings in Boston. So I wanted to flag that for you.

Second is prior to departure from the White House today, the President received a briefing on the latest — on the investigation into the bombings in Boston from his Homeland Security Advisor, Lisa Monaco. As you know, over the course of the last couple of days, the President has been routinely briefed on these latest details, and so he got his latest briefing this morning in person prior to leaving the White House.

The third thing is many of you have asked whether or not the President will have the opportunity while he’s in Boston to meet with the families of those who were injured or killed in the bombings. He will have that opportunity while he’s in Boston. He'll also have the opportunity to talk to some of the first responders, both professionals as well as the volunteers who were the first on the scene and were there to tend to those who were injured in the blasts.

I don't have any details for you at this point about where and when those meetings and those visits will occur, but over the course of the day we'll keep you updated on the President’s activities.

The last thing is I wanted to just give you a sense of who’s aboard Air Force one with us today. Several members of the Massachusetts congressional delegation are onboard. So both Massachusetts senators — Senator Elizabeth Warren and Senator Mo Cowan are aboard Air Force One this morning. Also aboard are Congressman Michael Capuano, Congressman Steven Lynch, Congressman Richard Neal, Congressman Bill Keating, and Congressman John Tierney. And then also aboard the plane is Vickie Kennedy, the wife of the late Massachusetts Senator Ted Kennedy.

Those are all the updates I have at this point. So we'll open it up for questions.

Q Josh, do you guys have any update on the West, Texas situation? Was the President briefed on it? And at this point, are you guys looking at this as an accident, or any kind of possible suspicious activity there?

MR. EARNEST: Well, let me start by saying that the thoughts and prayers of the President and First Lady go out to those who were affected by the blast that we saw in West, Texas last evening. It is clear just from the reports that the devastation there is quite significant and the Federal

From: http://www.whitehouse.gov/the-press-office/2013/04/18/press-gaggle-principal-deputy-press-secretary-josh-earnest-aboard-air-fo

American Express Profit Boosted by Higher Cardmember Spending

By Reuters

Filed under: , , , ,

Getty Images

Credit card company American Express Co.’s quarterly revenue came in below analyst expectations as cardmember spending growth remained muted.

Cardmember spending in the first quarter increased 7 percent, adjusted for foreign currency translations. This was the fourth successive quarter of single-digit growth after nine quarters of double-digit growth.

Expense accounts have come under greater scrutiny as companies look to cut costs to protect profit margins, hurting the credit card lender, which gets more than a quarter of its U.S. billed business from affluent corporate customers.

However, American Express‘s billed business was up 6 percent at $224.5 billion and total cards in force crossed 100 million during the quarter.

The company has the lowest delinquency rate among the large credit card companies, including JPMorgan Chase & Co. (JPM), Discover Financial Services, Capital One Financial Corp. (COF), Bank of America Corp. (BAC) and Citigroup Inc. (C).

It set aside $497 million to cover future bad loans in the quarter, 21 percent more than it had provisioned last year, reflecting its larger lending portfolio.

American Express Co. (AXP), which lends directly to consumers and also competes with Visa Inc. (V) and MasterCard Inc. (MA) to process credit card transactions, said global network and merchant services revenue increased 4 percent to $1.3 billion.

Sponsored Linksadsonar_placementId=1505951;adsonar_pid=1990767;adsonar_ps=-1;adsonar_zw=242;adsonar_zh=252;adsonar_jv=’ads.tw.adsonar.com’;

Consolidated expenses during the quarter remained in check, rising marginally, as the company looks to control costs and maintain a leaner operating structure.

The company said in January it would cut about 5,400 jobs as part of a global restructuring and took a related $600 million charge.

Profit for the quarter ended March 31 rose to $1.28 billion, or $1.15 a share, from $1.26 billion, or $1.07 a share, a year earlier.

Total revenue, net of interest expense, increased 4 percent to $7.88 billion.

Analysts on average had expected earnings of $1.12 a share on revenue of $8.03 billion, according to Thomson Reuters I/B/E/S.

American Express shares were marginally down in trading after the bell. They closed Wednesday at $64.13 on the New York Stock Exchange.

%Gallery-183217%

Permalink | Email this | Linking Blogs | Comments

From: http://www.dailyfinance.com/2013/04/18/american-express-earnings/

Blackbaud Ranks Most Generous Online U.S. Cities for 2012

By Business Wirevia The Motley Fool

Filed under:

Blackbaud Ranks Most Generous Online U.S. Cities for 2012

Seattle again earns top spot for 2012

CHARLESTON, S.C.–(BUSINESS WIRE)– When it comes to charitable giving, some U.S. cities consistently rise to the top in their adoption of digital giving channels. Blackbaud (NASDAQ: BLKB) today released its fifth annual ranking of the Most Generous Online U.S. Cities based on 2012 online giving data from Blackbaud customers.

The rankings remain largely unchanged from last year’s analysis, with the top four cities holding firm. For a second straight year, Seattle, WA earned the top spot, followed by Alexandria, VA and Washington, DC. Minneapolis made the biggest strides, jumping four spots to enter the top 10 in 2012. Bellevue, WA dropped one position and out of the top 10.

The analysis ranks 265 cities with total population of more than 100,000 based on per capita online giving. More than $509 million was donated online by donors in the 265 major cities, a 15 percent jump from 2011.

The current rankings come from donations processed between Jan. 1 and Dec. 31, 2012.

Top Ten Most Generous Online US Cities

A ranking of large cities (population > 100,000) based on per capita online giving in 2012:

  1. Seattle, WA
  2. Alexandria, VA
  3. Washington, DC
  4. Arlington, VA
  5. Ann Arbor, MI (+1 spot)
  6. Cambridge, MA (-1 spot)
  7. Berkeley, CA
  8. San Francisco, CA
  9. St. Louis, MO (+1 spot)
  10. Minneapolis, MN (+4 spots)

“Online giving continues to be an important part of a nonprofit’s overall fundraising strategy,” said Steve MacLaughlin, director of Blacbkbaud’s Idea Lab. “While overall giving remains relatively flat, we continue to see double-digit growth in online giving and expect the trend to continue throughout the year.”

From a regional perspective based on the U.S. Census grouping of

From: http://www.dailyfinance.com/2013/04/11/blackbaud-ranks-most-generous-online-us-cities-for/

InVivo Therapeutics' CEO Scheduled to Appear on WCVB-TV in Boston Tonight

By Business Wirevia The Motley Fool

Filed under:

InVivo Therapeutics’ CEO Scheduled to Appear on WCVB-TV in Boston Tonight

CAMBRIDGE, Mass.–(BUSINESS WIRE)– InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that CEO Frank Reynolds is scheduled to appear on WCVB-TV in Boston tonight, April 10th during the 11:00pm EDT newscast.

InVivo Therapeutics has pioneered a treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after traumatic SCI.

Last week, the U.S. Food and Drug Administration (FDA) granted two approvals to the Company, the first for Humanitarian Use Device (HUD) designation, which the Company believes will expedite the product’s path to market, and the second to approve the Company to begin a first-in-man clinical trial of the technology.

“Our technology is a true platform that can be leveraged to create products for many neurotrauma conditions, and we look forward to beginning the study for our lead product to provide the first effective treatment option for acute SCI,” said Reynolds.

WCVB-TV is the ABC affiliate for the Boston market and airs locally on channel 5.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the expected approval of the FDA to conduct

Source: FULL ARTICLE at DailyFinance

What Will Obamacare Do to Medicare?

By Brandy Betz, The Motley Fool

Filed under:

Medicaid has stayed at the forefront of the Patient Protection and Affordable Care Act, or “Obamacare,” debate thanks to the number of states still battling against the proposed expansion. But how will the health care changes affect Medicare?

The short answer is that it depends on the type of Medicare. Traditional, government-backed Medicare includes parts A and B to cover both hospital stays and doctor visits. Private insurers offer prescription drug Part D plans and Medicare Advantage. Advantage plans typically combine the three lettered parts with some additional coverage areas, and they face the greatest risk of changes.

And it was the reversal of a seemingly adverse change behind a health plans rally last week. After an unfavorable government reimbursement decision for Medicare Advantage plans was reversed, shares of Humana and UnitedHealth Group surged to finish up 13% and 9% for the week, respectively.

Reactions like that suggest a deeper look into the specific changes posed by Obamacare. Here’s a quick guide to what the legislation will mean to government-administered Medicare plans, as well as their private insurance counterparts.

Parts A and B
Coverage for parts A and B will largely stay the same under Obamacare. But a few revisions kicked in last year that included free wellness checkups for the newly eligible. There’s also no longer a charge for part B patients needing flu shots or screenings for a range of conditions such as diabetes, cervical cancer, or high cholesterol.

The cost of these programs for beneficiaries will grow slower under Obamacare, thanks to overpayment restrictions for hospitals and physicians.

Part D
These prescription drug plans included a coverage gap, or donut hole, where patients had to pay out of pocket for a period. Obamacare will close those gaps by 2020 with increasing drug discounts that began last year.

Beneficiaries with active plans in 2011 received drug discounts during the donut hole that amounted to savings of 50% on branded drugs and 7% on generics. Here’s how those discounts will build up until the 2020 mark:

 

2012

2013

2014

2015

2016

2017

2018

2019

2020

Branded

50%

52.5%

52.5%

55%

55%

60%

65%

70%

75%

Generic

14%

21%

28%

35%

42%

49%

56%

63%

75%

Part D plans can be standalone or come bundled in a Medicare Advantage package. Let’s move into an MA explanation before we look at how the private insurers are involved in these two plan types.

Medicare Advantage
Predicting the future for MA is harder because the changes will vary according to the plan specifics and the insurer. It’s best for MA beneficiaries to contact the insurer for details.

What about MA from the standpoints of policy and business?

As I mentioned, Obamacare will limit overpayments to health care providers. But MA insurers also have to prove they’re using from 80% to 85% of revenues toward covering medical treatments. Those percentage numbers are called a medical

Source: FULL ARTICLE at DailyFinance

Pace Medical Completes Restructuring

By Business Wirevia The Motley Fool

Filed under:

Pace Medical Completes Restructuring

PLAINVILLE, Mass.–(BUSINESS WIRE)– Pace Medical (Pink Sheets: PMDL) announces completion of its facility relocation to Plainville, MA. The company has successfully integrated the resources and manufacturing strengths of its UK based subsidiary into its new US location. All R&D and manufacturing will be based out of Plainville. Devices Ltd, a UK based firm was appointed its Authorized European Representative.

“This completes the final stage of restructuring the Company’s R&D and manufacturing operations to provide product and support to our global customer base,” stated Steven Hanson, President & CEO.

“Our next phase will be new product introductions which will be highlighted at the up-coming Heart Rhythm Society meeting in Denver, Colorado this May,” added Mr. Hanson.

Pace Medical
Steven Hanson
+1 858-452-2222
pacemedicalinfo@gmail.com

KEYWORDS:   United Kingdom  United States  Europe  North America  Colorado  Massachusetts

INDUSTRY KEYWORDS:

The article Pace Medical Completes Restructuring originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
}
}

addEvent(window, "load", function(){new FoolVisualSciences();})
addEvent(window, "load", function(){new PickAd();})

var themeName = 'dailyfinance.com';
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-24928199-1']);
_gaq.push(['_trackPageview']);

(function () {

var ga = document.createElement('script');
ga.type = 'text/javascript';
ga.async = true;
ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';

…read more

Source: FULL ARTICLE at DailyFinance

PerkinElmer to Present Translating Data into Clinical Medicine at the Bio-IT World Conference

By Business Wirevia The Motley Fool

Filed under:

PerkinElmer to Present Translating Data into Clinical Medicine at the Bio-IT World Conference

WALTHAM, Mass.–(BUSINESS WIRE)– PerkinElmer, Inc. (NYS: PKI) , a global leader focused on improving the health and safety of people and the environment, today announced that the Company will present at the Bio-IT World Conference at 11:00AM eastern time on Wednesday, April 10, 2013 at the Seaport World Trade Center located at 200 Seaport Boulevard in Boston, MA.

Kevin Hrusovsky, president of PerkinElmer’s Life Sciences &Technology business, will be a featured speaker at the Bio-IT World Conference’s Cancer Informatics track. In his Tools for Revolutionizing Translational Cancer Medicine presentation, Mr. Hrusovsky will discuss how combining the “in vitro-to-in vivo-to human” continuum of research tools with a powerful informatics platform may successfully bridge the chasm from laboratory research to clinical applications, particularly in the field of cancer medicine and personalized health.

For more information, visit the Bio-IT World Conference website.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Edelman (on behalf of PerkinElmer)
Paul Barren, 404-460-9679
Paul.barren@edelman.com

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:

The article PerkinElmer to Present Translating Data into Clinical Medicine at the Bio-IT World Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
…read more

Source: FULL ARTICLE at DailyFinance

Weston Financial Says "Avoiding Tax Mistakes" Key to Financial Planning

By Business Wirevia The Motley Fool

Filed under:


Weston Financial Says “Avoiding Tax Mistakes” Key to Financial Planning


New White Paper Offers Tax Tips for 2013 Planning

WELLESELY, Mass.–(BUSINESS WIRE)– Weston Financial Group, Inc., a Wellesley, MA-based registered investment advisor with $1.6 billion under management, today released a white paper, “Avoid Tax Mistakes:Taxes Become Strategic for Financial Planning in 2013.”The paper highlights the two types of broad tax strategies and the eight common tax errors people should consider when reviewing their financial plans. The paper also discusses marginal, effective and situational rates, capital gains, managing IRAs, and risk of being enticed by new tax rules.

Information about the white paper, or Weston Financial services, is available by contacting Drew Bottaro , Esq., CFP ® , Weston Financial Group Vice President & Senior Financial Counselor, at 1-781-235-7055. Bottaro, who was recently named a Five Star Wealth Manager by Five Star Professional, has more than 20 years of experience as a financial planning professional.

Weston Financial, a division of Washington Trust Wealth Management , was founded in 1979 to assist affluent families, high net worth corporate executives, and professionals in managing their financial affairs. Weston’s team of wealth managers hold advanced degrees and designations, ranging from JD, MBA, CFP® practitioner, CPA, Masters in Taxation, and Chartered Financial Analyst®. Weston’s services include investment management, retirement planning, estate planning, and tax and risk management. Weston Financial is a division of The Washington Trust Company , the oldest community bank in the nation and is the largest independent bank headquartered in Rhode Island. The Washington Trust Company is a subsidiary of Washington Trust Bancorp, Inc ., NASDAQ Global Select: WASH, a $3.1 billion corporation headquartered in Rhode Island.

Washington Trust
Elizabeth B. Eckel, 401-348-1309
401-348-1407
Senior Vice President, Marketing
ebeckel@washtrust.com

KEYWORDS:   United States  North America  Connecticut  Massachusetts  Rhode Island

INDUSTRY KEYWORDS:

The article Weston Financial Says “Avoiding Tax Mistakes” Key to Financial Planning originally appeared on Fool.com.

Try any of our Foolish newsletter services free …read more

Source: FULL ARTICLE at DailyFinance

pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company

By Business Wirevia The Motley Fool

Filed under:

pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company

WATERTOWN, Mass.–(BUSINESS WIRE)– pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that it has signed a funded technology evaluation agreement with a leading global pharmaceutical company. The agreement will evaluate pSivida’s proprietary Durasert™ and Tethadur™ technologies for this pharmaceutical company’s select products in ophthalmology. The Durasert technology system delivers specific quantities of drugs directly to a target site in the body at controlled rates for predetermined periods of time ranging from weeks to months. Tethadur is pSivida’s proprietary technology for the delivery of proteins, peptides and antibodies.

“We are extremely pleased to be working with another global pharmaceutical company to apply our unique technologies to develop transformational products in ophthalmology,” said Dr. Paul Ashton, pSivida president and CEO.

pSivida has developed three of the four sustained release devices for retinal diseases that have been approved in either the US or Europe, the most recent being ILUVIEN®, partnered with Alimera and approved in multiple EU countries. Independently, pSivida is developing an injectable, sustained release product to treat uveitis affecting the back of the eye (posterior uveitis) and an injectable, bioerodible product to treat glaucoma and ocular hypertension in collaboration with Pfizer.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic Diabetic Macula Edema (DME), licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal, the U.K. and Spain and is awaiting authorization in Italy. ILUVIEN® for DME has not been approved in the US. pSivida plans to institute pivotal Phase III clinical trials for the treatment of posterior uveitis with the same micro-insert as ILUVIEN® for DME. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. pSivida’s two FDA-approved products, Retisert® and Vitrasert®, are implants that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, …read more

Source: FULL ARTICLE at DailyFinance

Causeway Capital Management Names Foster Corwith and Alessandro Valentini Portfolio Managers

By Business Wirevia The Motley Fool

Filed under:

Causeway Capital Management Names Foster Corwith and Alessandro Valentini Portfolio Managers

LOS ANGELES–(BUSINESS WIRE)– Causeway Capital Management LLC (“Causeway”), an asset management firm specializing in global equity investing, today announced the appointment of Foster Corwith and Alessandro Valentini as portfolio managers, effective April 1.

Corwith and Valentini will join Causeway’s six current fundamental portfolio managers–Sarah Ketterer, Harry Hartford, James Doyle, Jonathan Eng, Kevin Durkin, and Conor Muldoon–in managing client portfolios on a team basis.

“Foster and Alessandro have made many meaningful contributions to Causeway over the years, and we’re delighted to promote them to the portfolio management team,” said Sarah Ketterer, chief executive officer of Causeway. “We have an exceptionally talented investment team—analysts as well as portfolio managers—collaborating to achieve our clients’ long-term investment objectives.”

Foster Corwith joined Causeway in 2006 and is a director and fundamental portfolio manager responsible for investment research in the global industrials and consumer sectors. Prior to joining Causeway, Mr. Corwith was a research associate at Deutsche Asset Management, where he was responsible for researching consumer staples companies. From 2003 to 2004, Mr. Corwith was a project manager in the Corporate Services group of The Bank of New York. From 2001- 2003, Mr. Corwith was an analyst in Credit Suisse First Boston’s prime brokerage unit. Mr. Corwith has an MBA from the University of Chicago, a BA, cum laude, from Tufts University, and is a CFA charterholder.

Alessandro Valentini joined Causeway in 2006 and is a director and fundamental portfolio manager responsible for investment research in the global health care and financials sectors. Before coming to Causeway, Mr. Valentini worked as a research analyst at Thornburg Investment Management. From 2000 to 2004, Mr. Valentini worked as a financial analyst at Goldman Sachs in the European Equities Research-Sales division in New York. Mr. Valentini has an MBA from Columbia Business School, with honors, an MA in Economics from Georgetown University and a BS, magna cum laude, from Georgetown University. He is also a CFA charterholder.

About Causeway

Established in 2001, Los Angeles-based Causeway provides investment management services to corporations, pension plans, public retirement plans, Taft-Hartley pension plans, endowments and foundations, mutual funds, charities, private trusts, wrap fee programs, and other institutions. Causeway’s international and global value equity strategies use team-based, value-driven investment disciplines that combine in-depth research and analysis, active portfolio construction, and proprietary risk management. Causeway also manages a quantitative emerging markets equity strategy and a global absolute return strategy. The firm, wholly-owned by …read more
Source: FULL ARTICLE at DailyFinance

pSivida Reports on Resubmission to FDA of NDA for ILUVIEN® for Chronic Diabetic Macular Edema

By Business Wirevia The Motley Fool

Filed under:

pSivida Reports on Resubmission to FDA of NDA for ILUVIEN® for Chronic Diabetic Macular Edema

WATERTOWN, Mass.–(BUSINESS WIRE)– pSivida Corp. (NAS: PSDV) (ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc. reported the submission of its response to the second Complete Response Letter from the U.S. Food and Drug Administration (FDA) with respect to ILUVIEN® for chronic diabetic macular edema (DME).

Alimera reported in its 10-K filing that it submitted the response, which includes additional analyses of the risks and benefits of ILUVIEN based on the clinical data available from the previously completed Phase III studies (FAME), following a meeting with the FDA in the second quarter 2012. Alimera said that the resubmission focuses on the safety aspects of ILUVIEN and the population of patients with chronic DME. This is the same group for which marketing approval of ILUVIEN has been granted in six EU countries thus far. Alimera reported that it will communicate the Prescription Drug User Fee Act (PDUFA) date once it is known from the FDA and that Alimera does not plan to conduct additional trials for ILUVIEN for DME at this time.

“We are pleased to see the resubmission of the NDA to the FDA,” said Dr. Paul Ashton, president and CEO of pSivida Corp. “To date, we have received over $30m from Alimera from its license of ILUVIEN for DME, and if the FDA approves ILUVIEN, we would be entitled to an additional $25 million milestone payment as well as 20% of net profits, as defined, on any sales in the U.S. by Alimera.”

pSivida is entitled to the same net profit share on sales of ILUVIEN for DME by Alimera in the EU. Alimera has announced its intent to commercially launch ILUVIEN in Germany and for private patients in the UK in the second quarter of 2013, upon approval of the commercial batch size.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic Diabetic Macula Edema (DME), licensed to Alimera Sciences, Inc., has received marketing …read more
Source: FULL ARTICLE at DailyFinance

Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Sub

By Business Wirevia The Motley Fool

Filed under:

Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI)


– Study to evaluate NAV4694 in monitoring progression of MCI to Alzheimer’s Disease –

DUBLIN, Ohio–(BUSINESS WIRE)– Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography (PET) imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment (MCI). The study is designed to investigate whether NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with MCI who progress to Alzheimer’s disease (AD) from those who do not. Enrollment is currently planned at approximately five sites throughout the U.S. The first patient has been enrolled by the Alzheimer’s Disease Center at Quincy Medical Center in Quincy, MA.

“We are pleased to participate in this important clinical study of NAV4694 aimed at evaluating a patient population in whom dementia is just emerging and for whom it is believed the best prospects for therapeutic intervention will exist,” said Dr. Anil K. Nair, MD, Chief of Neurology and Head of the Alzheimer’s Disease Center at Quincy Medical Center in Quincy, MA. “Clinical trial results to date indicate that NAV4694 shows favorable sensitivity and specificity in detecting β-amyloid while exhibiting low white-matter uptake for clearer images that may assist in differential diagnoses associated with MCI. If AD could be diagnosed at an earlier stage, before clinical dementia has fully developed, the potential for successful intervention with current and future treatments could be improved considerably.”

“As the dementia field moves to earlier evaluation and treatment of cognitive impairment, it is of increasing importance to have diagnostic agents that can accurately detect the underlying cause. To our knowledge this is the first prospective, multi-center study to evaluate a radiopharmaceutical β-amyloid agent solely in subjects with MCI, an area of extreme importance as Alzheimer’s disease is expected to impact as many as 14 million Americans by 2050,” commented Cornelia Reininger, MD, PhD, Navidea’s Senior Vice President and Chief Medical Officer. “The outcome of this trial may enable accurate differentiation of MCI subjects who are at risk of developing Alzheimer’s disease from those who are not before the disease has reached more advanced stages that can impair activities of daily living. Our ultimate goal is …read more
Source: FULL ARTICLE at DailyFinance